EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A Case of Lung Squamous Cell Carcinoma Harboring TP53 Mutation and PLPP5‐FGFR1 Fusion Gene

Meng Xiao-Ru, Shi Xiao-Xiong, Gao Qian, Qu Ya-Jing, Huo Li-Li, Gao Yan-Yan, Xu Peng-Peng, Ma Guan-Nan, Ren Gui-Bing iD

The Clinical Respiratory Journal · 2025

DOI: 10.1111/crj.70074 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Clinical Respiratory Journal, 2025. Verfasst von Meng Xiao-Ru und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Receptor, Fibroblast Growth Factor, Type 1, Carcinoma, Squamous Cell, Tumor Suppressor Protein p53. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung squamous cell carcinoma (LUSC) is one of the most common subtype of lung cancer and is associated with the poor prognoses. The fibroblast growth factor receptor (FGFR) family is known to be activated through fusions with various partners across multiple cancer types, including nonsmall cell lung cancer (NSCLC). FGFR inhibitors are currently undergoing clinical evaluation for the treatment of tumors harboring these fusions. While FGFR1 amplification has been well‐documented in numerous NSCLC datasets, the characterization of specific FGFR fusion variants remains limited. In this study, we identified a novel PLPP5‐FGFR1 fusion in a 65‐year‐old male patient with lung squamous cell carcinoma through targeted RNA sequencing. The fusion junction was located between exon 1 of PLPP5 and exon 5 of FGFR1, and the result was validated by Sanger sequencing. To our knowledge, this is the first reported case of a PLPP5‐FGFR1 fusion coexisting with a TP53 mutation in LUSC. These findings broaden the spectrum of potential translocation partners in FGFR1 fusions, and the clinical implications of this novel fusion on treatment outcomes and prognosis warrant further investigation and long‐term follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsReceptor, Fibroblast Growth Factor, Type 1Carcinoma, Squamous CellTumor Suppressor Protein p53Oncogene Proteins, FusionCarcinoma, Non-Small-Cell LungHumansMaleAgedMutation

Stichwörter der Autor:innen

PLPP5‐FGFR1 fusion geneTP53 mutationlung squamous cell carcinoma

Substanzen

Receptor, Fibroblast Growth Factor, Type 1FGFR1 protein, humanTumor Suppressor Protein p53TP53 protein, humanOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Oncology Department, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, China.
  • Medical Research Center Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, China.

ORCID-Profile: Ren Gui-Bing

Zitieren

APA

Xiao-Ru, M., Xiao-Xiong, S., Qian, G., Ya-Jing, Q., Li-Li, H., Yan-Yan, G., Peng-Peng, X., Guan-Nan, M., & Gui-Bing, R. (2025). A Case of Lung Squamous Cell Carcinoma Harboring TP53 Mutation and PLPP5‐FGFR1 Fusion Gene. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70074

Vancouver

Xiao-Ru M, Xiao-Xiong S, Qian G, Ya-Jing Q, Li-Li H, Yan-Yan G, et al. A Case of Lung Squamous Cell Carcinoma Harboring TP53 Mutation and PLPP5‐FGFR1 Fusion Gene. The Clinical Respiratory Journal. 2025. doi:10.1111/crj.70074

BibTeX
@article{XiaoRu2025,
  author = {Xiao-Ru, Meng and Xiao-Xiong, Shi and Qian, Gao and Ya-Jing, Qu and Li-Li, Huo and Yan-Yan, Gao and Peng-Peng, Xu and Guan-Nan, Ma and Gui-Bing, Ren},
  title = {A Case of Lung Squamous Cell Carcinoma Harboring TP53 Mutation and PLPP5‐FGFR1 Fusion Gene},
  journal = {The Clinical Respiratory Journal},
  year = {2025},
  doi = {10.1111/crj.70074}
}
Kostenlos starten →